Quantcast
Home > Quotes > EVOK
EVOK

Evoke Pharma, Inc. Common Stock (EVOK) Quote & Summary Data

$3.04
*  
0.10
3.4%
Get EVOK Alerts
*Delayed - data as of Feb. 15, 2019  -  Find a broker to begin trading EVOK now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
7
Today's High / Low
$ 3.05 / $ 2.92
Share Volume
57,039
50 Day Avg. Daily Volume
37,704
Previous Close
$ 2.94
52 Week High / Low
$ 3.40 / $ 1.85
Market Cap
52,979,700
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.91

Intraday Chart

Shares Traded

Share Volume:
57,039
50 Day Avg. Daily Volume:
37,704

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.43

Trading Range

The current last sale of $3.04 is 64.32% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.05 $ 3.40
 Low: $ 2.92 $ 1.85

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. We are developing Gimoti, an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Diabetic gastroparesis is a GI disorder afflicting millions of individuals worldwide and is characterized by slow or delayed gastric emptying and evidence of gastric retention in the absence of mechanical obstruction and can cause various serious digestive system symptoms and other complications. Metoclopramide tablets and injection are the only products currently approved in the United States to treat the symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.  ... More ...  


Risk Grade

Where does EVOK fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.97
Open Date:
Feb. 15, 2019
Close Price:
$ 3.04
Close Date:
Feb. 15, 2019

Consensus Recommendation

Analyst Info